1. Public Health England.NHS Sickle Cell and Thalassaemia Screening Programme Data Report 2016 to 2017: trends and performance analysis [Internet]. London; 2018 [cited 2022 Aug 16]. Available from:https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/713120/SCT_data_report_2016_to_2017.pdf
2. National Institute for Health and Care Excellence.Crizanlizumab for preventing sickle cell crises in sickle cell disease: Technology appraisal guidance TA743 [Internet] [Internet]. London; 2021 [cited 2022 Aug 16]. Available from:https://www.nice.org.uk/guidance/ta743
3. Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease
4. All‐Party Parliamentary Group on Sickle Cell and Thalassaemia (SCTAPPG) The Sickle Cell Society. No one's listening: an inquiry into the avoidable deaths and failures of care for sickle cell patients in secondary care [Internet].2021[cited 2022 Aug 16]. Available from:https://www.sicklecellsociety.org/wp‐content/uploads/2021/11/No‐Ones‐Listening‐Final.pdf
5. Public Health England.Beyond the data: Understanding the impact of COVID‐19 on BAME groups [Internet].2020[cited 2022 Aug 16]. Available from:https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/892376/COVID_stakeholder_engagement_synthesis_beyond_the_data.pdf